A Cochrane review included 76 studies with a total of 14 412 subjects. As compared with placebo (9 studies, n=1 109), women using oral misoprostol (OM)(a synthetic prostaglandin E1 analogue) were more likely to deliver vaginally within 24 hours (RR 0.16, 95% CI 0.05 to 0.49; 1 trial, n=96), needed less oxytocin (RR 0.42, 95% CI 0.37 to 0.49; 7 trials, n=933) and had a lower caesarean section rate (RR 0.72, 95% CI 0.54 to 0.95; 8 trials, n=1029).As compared with vaginal dinoprostone (12 studies, n=3 859), women given OM were less likely to need a caesarean section (RR 0.88, 95% CI 0.78 to 0.99; 11 trials, n=3 592).There was some evidence that they had slower inductions, but there were no other significant differences. As compared with intravenous oxytocin (9 studies, n=1 282 ),the caesarean section rate was significantly lower in women who received oral misoprostol (RR 0.77, 95% CI 0.60 to 0.98; 9 trials, n=1282), butthey had an increase in meconium-stained liquor (RR 1.65, 95% CI 1.04 to 2.60; 7 trials, n=1 172). 37 studies (n=6 417) compared oral and vaginal misoprostol and found no difference in the primary outcomes. However there were fewer babies born with a low Apgar score in the OM group (RR 0.60, 95% CI 0.44 to 0.82; 19 trials, 4009 babies).